Drugs / Autologous Human Schwann Cells
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03999424 | Sep 2019 → Dec 2025 | peripheral nerve lesion | W. Dalton Dietrich | Completed | No outcome recorded |
| Phase 1 | NCT02354625 | Jan 2015 → Aug 2019 | paraplegia, quadriplegia, spinal cord injury | W. Dalton Dietrich | Completed | No outcome recorded |
| Phase 1 | NCT01739023 | Nov 2012 → Aug 2016 | paraplegia, spinal cord injury | W. Dalton Dietrich | Completed | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT04465929 | — | peripheral nerve lesion | W. Dalton Dietrich | No longer available | No outcome recorded |
| — | NCT02480777 | — | lesion of sciatic nerve | W. Dalton Dietrich | No longer available | No outcome recorded |
| — | NCT02510079 | — | sciatic neuropathy | W. Dalton Dietrich | No longer available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Human Schwann Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04465929 ↗ |
| Known as | ahSC | “As a part of a Phase I clinical trial to assess the safety of autologous human Schwann cells (ahSC) in persons with chronic spinal cord injury (SCI), participants engaged in a...” PMID 32493977 ↗ Jun 20201“autologous human Schwann cells (ahSC) transplantation” NCT01739023 ↗ |
| Action | Restore | “For humans with chronic SCI, we hypothesize that axons might show improved function if myelin repair is induced with the implantation of ahSC.” NCT02354625 ↗ |
| Modality | Cell therapy | “cell-based treatment strategy” NCT01739023 ↗ |
| Route | Other | “administered via a single injection into the cavity of the spinal cord lesion” NCT01739023 ↗ |